Search

Your search keyword '"Adelstein, David J."' showing total 679 results
Start Over Author "Adelstein, David J."
679 results on '"Adelstein, David J."'

103. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck

Author

Adelstein, David J., Lavertu, Pierre, Saxton, Jerrold P., Secic, Michelle, Wood, Benjamin G., Wanamaker, John R., Eliachar, Isaac, Strome, Marshall, and Larto, Marjorie A.

Subjects
Head and neck cancer -- Care and treatment, Radiotherapy -- Evaluation, Squamous cell carcinoma -- Care and treatment, Health
Published
2000

106. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion

Author

Adelstein, David J., primary, Ismaila, Nofisat, additional, Ku, Jamie A., additional, Burtness, Barbara, additional, Swiecicki, Paul L., additional, Mell, Loren, additional, Beitler, Jonathan J., additional, Gross, Neil, additional, Jones, Christopher U., additional, Kaufman, Marnie, additional, Le, Quynh-Thu, additional, Semrad, Thomas J., additional, Siu, Lillian L., additional, and Ridge, John A., additional

Published
2019
Full Text
View/download PDF

108. Clinical Factors Associated With Cost in Head and Neck Cancer: Implications for a Bundled Payment Model

Author

Tom, Martin C., primary, Ross, Richard B., additional, Koyfman, Shlomo A., additional, Adelstein, David J., additional, Lorenz, Robert R., additional, Burkey, Brian B., additional, Shah, Chirag, additional, Suh, John H., additional, Bolwell, Brian J., additional, Savage, Craig, additional, Platz, Scott, additional, and Ward, Matthew C., additional

Published
2019
Full Text
View/download PDF

109. Outcomes of postoperative treatment with concurrent chemoradiotherapy (CRT) in high risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration.

Author

Geiger, Jessica Lyn, primary, Woody, Neil McIver, additional, Tsai, C. Jillian, additional, Ghanem, Ahmed I., additional, Dunlap, Neal, additional, Liu, Howard, additional, Burkey, Brian B., additional, Lamarre, Eric, additional, Ku, Jamie, additional, Scharpf, Joseph, additional, Joshi, Nikhil Purushottam, additional, Caudell, Jimmy J., additional, Siddiqui, Farzan, additional, Porceddu, Sandro, additional, Lee, Nancy Y., additional, Koyfman, Shlomo A., additional, and Adelstein, David J., additional

Published
2019
Full Text
View/download PDF

110. Incidence of severe late toxicities of head and neck squamous cell cancer (HNSCC) treatment in the era of intensity modulated radiotherapy (IMRT).

Author

Eziokwu, Akaolisa Samuel, primary, Koyfman, Shlomo A., additional, Reddy, Chandana A., additional, Matia, Brian, additional, Woody, Neil McIver, additional, Joshi, Nikhil Purushottam, additional, Burkey, Brian B., additional, Scharpf, Joseph, additional, Lamarre, Eric, additional, Prendes, Brandon, additional, Lorenz, Robert, additional, Ku, Jamie, additional, Adelstein, David J., additional, and Geiger, Jessica Lyn, additional

Published
2019
Full Text
View/download PDF

112. Preliminary safety results of a phase II study investigating pembrolizumab in combination with postoperative intensity modulated radiotherapy (IMRT) in resected high risk cutaneous squamous cell cancer of the head and neck.

Author

Koyfman, Shlomo A., primary, Gastman, Brian, additional, Vidimos, Allison T., additional, Joshi, Nikhil Purushottam, additional, Lucas, Jennifer, additional, Poblete-Lopez, Christine, additional, Vij, Alok, additional, Meine, Jon, additional, Burkey, Brian B., additional, Ku, Jamie, additional, Lamarre, Eric, additional, Prendes, Brandon, additional, Scharpf, Joseph, additional, Billings, Steven D, additional, Samsa, Julia, additional, Robinson, Shelley Beth, additional, Adelstein, David J., additional, and Geiger, Jessica Lyn, additional

Published
2019
Full Text
View/download PDF

113. Outcomes of post-operative treatment with concurrent systemic therapy and radiotherapy (RT) in intermediate (INT) risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration.

Author

Geiger, Jessica Lyn, primary, Woody, Neil McIver, additional, Tsai, C. Jillian, additional, Ghanem, Ahmed I., additional, Dunlap, Neal, additional, Liu, Howard, additional, Burkey, Brian B., additional, Lamarre, Eric, additional, Ku, Jamie, additional, Scharpf, Joseph, additional, Joshi, Nikhil Purushottam, additional, Caudell, Jimmy J., additional, Siddiqui, Farzan, additional, Porceddu, Sandro, additional, Lee, Nancy Y., additional, Koyfman, Shlomo A., additional, and Adelstein, David J., additional

Published
2019
Full Text
View/download PDF

114. T2N0M0 esophageal cancer

Author

Rice, Thomas W., Mason, David P., Murthy, Sudish C., Zuccaro, Gregory, Jr, Adelstein, David J., Rybicki, Lisa A., and Blackstone, Eugene H.

Published
2007

115. Data Set for the Reporting of Carcinomas of the Nasopharynx and Oropharynx: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting

Author

Lewis, James S., primary, Adelstein, David J., additional, Agaimy, Abbas, additional, Carlson, Diane L., additional, Faquin, William C., additional, Helliwell, Tim, additional, Hille, Jos, additional, Ng, Tony, additional, Nicholls, John M., additional, O'Sullivan, Brian, additional, and Thompson, Lester D. R., additional

Published
2018
Full Text
View/download PDF

116. Suboptimal Outcomes in Cutaneous Squamous Cell Cancer of the Head and Neck with Nodal Metastases

Author

VARRA, VAMSI, primary, WOODY, NEIL M., additional, REDDY, CHANDANA, additional, JOSHI, NIKHIL P., additional, GEIGER, JESSICA, additional, ADELSTEIN, DAVID J., additional, BURKEY, BRIAN B., additional, SCHARPF, JOSEPH, additional, PRENDES, BRANDON, additional, LAMARRE, ERIC D., additional, LORENZ, ROBERT, additional, GASTMAN, BRIAN, additional, MANYAM, BINDU V., additional, and KOYFMAN, SHLOMO A., additional

Published
2018
Full Text
View/download PDF

120. Evaluating compliance with process‐related quality metrics and survival in oral cavity squamous cell carcinoma: Multi‐institutional oral cavity collaboration study.

Author

Liu, Sara W., Woody, Neil M., Wei, Wei, Appachi, Swathi, Contrera, Kevin J., Tsai, Jillian C., Ghanem, Ahmed I., Matia, Brian, Joshi, Nikhil P., Geiger, Jessica L., Ku, Jamie A., Burkey, Brian B., Scharpf, Joseph, Prendes, Brandon L., Caudell, Jimmy J., Dunlap, Neal E., Adelstein, David J., Porceddu, Sandro, Liu, Howard, and Siddiqui, Farzan

Subjects
MOUTH, SQUAMOUS cell carcinoma, PROPORTIONAL hazards models, HEAD & neck cancer, PROGNOSIS
Abstract

Background: Process‐related measures have been proposed as quality metrics in head and neck cancer care. A recent single‐institution study identified four key metrics associated with increased survival. This study sought to validate the association of these quality metrics with survival in a multi‐institutional cohort. Methods: Multicenter retrospective study of patients with oral cavity squamous cell (1/2005‐1/2015). Baseline patient and disease characteristics and compliance with quality metrics was evaluated. Association between compliance with quality metrics with overall survival (OS), disease‐free survival (DFS), and disease‐specific survival (DSS) was evaluated using Cox proportional hazards models. Results: Failure to comply with two or more of the quality metrics was associated with worse OS, DFS, and DSS. Adherence to all or all but one of the quality metrics was found to be associated with improved survival. Conclusions: Process‐related quality metrics are associated with increased survival in patients with oral cavity squamous cell carcinoma in a multi‐institutional cohort. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

124. Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy.

Author

Sharrett, Jonathan M., Ward, Matthew C., Murray, Eric, Scharpf, Joseph, Lamarre, Eric D., Prendes, Brandon L., Lorenz, Robert R., Burkey, Brian B., Koyfman, Shlomo A., Woody, Neil M., Greskovich, John F., Adelstein, David J., Geiger, Jessica L., and Joshi, Nikhil P.

Abstract

Objective: To investigate the association between tumor volume and locoregional failure (LRF) after concurrent chemoradiation (CCRT) for locally advanced larynx cancer (LC).Methods: This is a retrospective cohort study from 2009 to 2014 identified from an institutional review board-approved registry. Fifty-nine of 68 patients with locally advanced larynx cancer treated with definitive CCRT who had available imaging for review were identified. The main endpoint to be assessed was the association between gross tumor volumes (GTV; T = total, P = primary, N = nodal) and LRF. Receiver operative characteristic (ROC) curves were used to investigate diagnostic accuracy.Results: Twenty LRFs were observed, resulting in a 2-year LRF rate of 39% (95% CI, 23-52%). On UVA, the GTV-T (P = .01), GTV-P (P = .05), and GTV-N (P = .04) were statistically significant predictors of LRF. Furthermore, age, smoking status, N-stage, larynx subsite, and tracheostomy/feeding tube dependence were potentially associated with LRF (P < .3), whereas T-stage (T3-4 vs. T2) was not (HR 1.05, 95% CI, 0.38-2.91, P = .92). In the multivariable model, GTV-P (HR 1.022, 95% CI, 0.999-1.046, P = .07) and GTV-N (HR 1.053, 95% CI, 1.0004-1.108, P = .05) were the two most impactful covariates on the model's R2 . ROC analysis suggested an optimal cut point of 12 cc in the GTV-T. The 2-year LRF for GTV-T > 12 cc was 64.2% and ≤ 12 cc was 16.4%, P = .006.Conclusion: GTV is associated with LRF after definitive CCRT for LC. Patients with bulky primary and/or nodal tumors may be better served with upfront surgical resection regardless of T-stage. Further investigation into the safety of larynx preservation for low-volume T4 tumors can be considered.Level Of Evidence: 4 Laryngoscope, 130:2372-2377, 2020. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

125. Aggressive concurrent chemoradiotherapy and surgical resection for proximal esophageal squamous cell carcinoma

Author

Adelstein, David J., Rice, Thomas W., Tefft, Melvin, Koka, Anuradha, Van Kirk, Marjorie A., Kirby, Thomas J., and Taylor, Marie E.

Subjects
Esophageal cancer -- Care and treatment, Squamous cell carcinoma -- Care and treatment, Combined modality therapy -- Evaluation, Health
Abstract

Background. Proximal esophageal cancer has been a disease associated with relatively poor treatment success, partly due to advanced disease at presentation and the morbidity of the surgery required. Therefore, most patients receive palliative radiation therapy, and disease control is poor. Methods. Between July 1990 and December 1992, nine consecutive patients with proximal esophageal squamous cell carcinoma were treated with aggressive concurrent chemoradiotherapy followed by surgical resection. Treatment consisted of cisplatin (20 mg/[m.sup.2]/day) and 5-fluorouracil (1000 mg/[m.sup.2]/day), both given as continuous intravenous infusions over 4 days concurrent with accelerated fractionation external beam radiation therapy (150 cGy twice a day to a dose of 2400 cGy). Three weeks after beginning treatment, a second course of chemotherapy and accelerated fractionation radiation therapy was administered to a total preoperative radiation therapy dose of 4500 cGy. After restaging of their disease, patients next underwent surgical resection. A single postoperative course of chemotherapy and 2400 cGy of concurrent accelerated fractionation radiation therapy was administered to those patients with residual tumor in the resection specimen. Two of these nine patients also were given 4-day etoposide infusions (75 mg/[m.sup.2]/day) as part of their chemotherapy and received lower induction radiation therapy doses. Results. Although significant toxicity was experienced, there were no deaths attributable to the chemoradiotherapy and only one perioperative death. All nine patients underwent surgery; five required pharyngolaryngoesophagectomy. No residual tumor was found in the resection specimen in three of the nine patients. Continuous locoregional tumor control was achieved in all patients. Only two developed distant metastases. Conclusions. These results, using aggressive multi-modality treatment, suggest that excellent locoregional control and long term, disease free survival can be achieved in selected patients with proximal esophageal cancer. Cancer 1994; 74:1680-5.

Published
1994

126. Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer: results and surgical implications

Author

Adelstein, David J., Sharan, Vishwa M., Damm, Catherine, Earle, A. Scott, Shah, Ajit C., Haria, Chandra D., Trey, Joan E., Carter, Susan G., and Hines, John D.

Subjects
Head and neck cancer -- Radiotherapy, Squamous cell carcinoma -- Radiotherapy, Cisplatin -- Physiological aspects, Fluorouracil -- Physiological aspects, Radiotherapy -- Prognosis, Chemotherapy, Combination -- Usage, Health
Published
1992

127. Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials From a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

Author

Bauman, Julie E, Cohen, Ezra, Ferris, Robert L, Adelstein, David J, Brizel, David M, Ridge, John A, O'Sullivan, Brian, Burtness, Barbara A, Butterfield, Lisa H, Carson, William E, Disis, Mary L, Fox, Bernard A, Gajewski, Thomas F, Gillison, Maura L, Hodge, James W, Le, Quynh-Thu, Raben, David, Strome, Scott E, Lynn, Jean, and Malik, Shakun

Subjects
Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Antibodies, Article, Rare Diseases, Clinical Research, Monoclonal, Humans, Immunologic Factors, Molecular Targeted Therapy, Oncology & Carcinogenesis, Dental/Oral and Craniofacial Disease, human papillomavirus, Neoplasm Staging, Cancer, Clinical Trials as Topic, clinical trials, Patient Selection, Combined Modality Therapy, United States, National Cancer Institute (U.S.), Treatment Outcome, Good Health and Well Being, Head and Neck Neoplasms, Public Health and Health Services, head and neck cancer, immunotherapy, checkpoint inhibitors
Abstract

Recent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents are being rapidly adopted by the oncologic community and hold considerable promise. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with previously untreated, human papillomavirus-initiated oropharyngeal cancers; those with previously untreated, human papillomavirus-negative HNSCC; and those with recurrent/metastatic HNSCC. In addition, a separate committee was formed to develop integrative biomarkers for the clinical trials. The meeting started with an overview of key immune components and principles related to HNSCC, including immunosurveillance and immune escape. Four clinical trial concepts were developed at the meeting integrating different immunotherapies with existing standards of care. These designs were presented for implementation by the head and neck committees of the National Cancer Institute-funded National Clinical Trials Network. This article summarizes the proceedings of this Clinical Trials Planning Meeting, the purpose of which was to facilitate the rigorous development and design of randomized phase 2 and 3 immunotherapeutic trials in patients with HNSCC. Although reviews usually are published immediately after the meeting is held, this report is unique because there are now tangible clinical trial designs that have been funded and put into practice and the studies are being activated to accrual. Cancer 2017;123:1259-1271. © 2016 American Cancer Society.

Published
2016

129. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer

Author

Adelstein, David J., Sharan, Vishwa M., Earle, A. Scott, Shah, Ajit C., Vlastou, Catherine, Haria, Chandra D., Damm, Catherine, Carter, Susan G., and Hines, John D.

Subjects
Squamous cell carcinoma -- Care and treatment, Head and neck cancer, Chemotherapy -- Dosage and administration, Radiotherapy -- Dosage and administration, Squamous cell carcinoma -- Prognosis, Health
Abstract

Squamous cell cancers of the head and neck are generally responsive to chemotherapy, radiation, or both. However, not all schedules of treatment work equally well. To evaluate the relative effectiveness of two schedules of combination radiation and chemotherapy, 48 patients with locally confined squamous cell carcinoma of the head and neck were randomly assigned to one of two experimental groups. The first group received chemotherapy and radiotherapy simultaneously, followed by another course of simultaneous chemo- and radiotherapy. The second, or sequential, group, received chemotherapy first, followed by radiotherapy. Chemotherapy consisted of cycles of 5-fluorouracil and cisplatin; radiotherapy consisted of a total of 6,000 cGy (a Gy, or Gary, is 1 joule of energy absorbed per kilogram of tissue). Patients who achieved complete remission after the first treatment cycle did not receive surgery; in addition, five patients either had unresectable tumors or refused surgery. The data indicate an improved relapse-free survival rate for the patients who received simultaneous treatment. However, it is too early to determine if the relapse-free survival will translate into significantly improved overall survival. The toxicity of the two treatment schedules was comparable, although the simultaneous chemo- and radiotherapy group had more inflammation of the mucous membranes and greater weight loss. The study demonstrates that simultaneous chemo- and radiotherapy may provide an advantage for treating squamous cell carcinoma of the head and neck. Furthermore, the study found that the appropriate scheduling of treatment can reduce the need for surgery without affecting the patient's relapse-free survival. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

130. Impact of active smoking on outcomes in HPV+ oropharyngeal cancer.

Author

Xiao, Roy, Pham, Yvonne, Ward, Matthew C., Houston, Narcissa, Reddy, Chandana A., Joshi, Nikhil P., Greskovich, John F., Woody, Neil M., Chute, Deborah J., Lamarre, Eric D., Prendes, Brandon L., Lorenz, Robert R., Scharpf, Joseph, Burkey, Brian B., Geiger, Jessica L., Adelstein, David J., and Koyfman, Shlomo A.

Subjects
SMOKING, SQUAMOUS cell carcinoma
Abstract

Background: The role of smoking among patients with human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) is unclear. Methods: A retrospective cohort study of patients with HPV(+) OPSCC from 2001 to 2015 at a tertiary‐care institution was conducted. The primary outcome was overall survival (OS). Results: Among 484 included patients, 94 (19.4%) were active smokers, 226 (46.7%) were former smokers, and 164 (33.9%) never smoked. Among active smokers, 82 patients (87.2%) had a ≥10 pack‐year and 69 (73.4%) had a ≥20 pack‐year smoking history. After adjusting for covariates, active smoking was a significant predictor of inferior OS (HR 2.28, P <.001) and PFS (HR 2.26, P <.001). When including pack‐years as the covariate, ≥20 pack‐years predicted a decreased effect‐size for inferior OS and PFS. Conclusions: For patients with HPV(+) OPSCC, active smoking at diagnosis is the most powerful covariate capturing smoking history to predict OS and PFS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

132. Case Report: Primary Orbital Squamous Cell Carcinoma

Author

Blandford, Alexander D., primary, Bellerive, Claudine, additional, Tom, Martin, additional, Koyfman, Shlomo, additional, Adelstein, David J., additional, Plesec, Thomas P., additional, Perry, Julian D., additional, and Singh, Arun D., additional

Published
2018
Full Text
View/download PDF

133. Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al

Author

Molenaar, Remco J., primary, Sidana, Surbhi, additional, Radivoyevitch, Tomas, additional, Gerds, Aaron T., additional, Carraway, Hetty E., additional, Kalaycio, Matt, additional, Nazha, Aziz, additional, Adelstein, David J., additional, Nasr, Christian, additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneed S., additional, Sekeres, Mikkael A., additional, and Mukherjee, Sudipto, additional

Published
2018
Full Text
View/download PDF

134. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer

Author

Molenaar, Remco J., primary, Sidana, Surbhi, additional, Radivoyevitch, Tomas, additional, Advani, Anjali S., additional, Gerds, Aaron T., additional, Carraway, Hetty E., additional, Angelini, Dana, additional, Kalaycio, Matt, additional, Nazha, Aziz, additional, Adelstein, David J., additional, Nasr, Christian, additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneet S., additional, Sekeres, Mikkael A., additional, and Mukherjee, Sudipto, additional

Published
2018
Full Text
View/download PDF

135. Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity

Author

JULOORI, ADITYA, primary, KOYFMAN, SHLOMO A., additional, GEIGER, JESSICA L., additional, JOSHI, NIKHIL P., additional, WOODY, NEIL M., additional, BURKEY, BRIAN B., additional, SCHARPF, JOSEPH, additional, LAMARRE, ERIC L., additional, PRENDES, BRANDON, additional, ADELSTEIN, DAVID J., additional, GRESKOVICH, JOHN F., additional, and KELLER, LANEA, additional

Published
2018
Full Text
View/download PDF

138. Response to ASTRO consensus guideline for oropharyngeal cancer

Author

Sher, David J., primary, Adelstein, David J., additional, Bajaj, Gopal K., additional, Brizel, David M., additional, Cohen, Ezra E., additional, Halthore, Aditya, additional, Harrison, Louis B., additional, Lu, Charles, additional, Moeller, Benjamin J., additional, Quon, Harry, additional, Rocco, James W., additional, Sturgis, Erich M., additional, Tishler, Roy B., additional, Trotti, Andy, additional, Waldron, John, additional, and Eisbruch, Avraham, additional

Published
2018
Full Text
View/download PDF

139. Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Author

Forastiere, Arlene A., primary, Ismaila, Nofisat, additional, Lewin, Jan S., additional, Nathan, Cherie Ann, additional, Adelstein, David J., additional, Eisbruch, Avraham, additional, Fass, Gail, additional, Fisher, Susan G., additional, Laurie, Scott A., additional, Le, Quynh-Thu, additional, O’Malley, Bernard, additional, Mendenhall, William M., additional, Patel, Snehal, additional, Pfister, David G., additional, Provenzano, Anthony F., additional, Weber, Randy, additional, Weinstein, Gregory S., additional, and Wolf, Gregory T., additional

Published
2018
Full Text
View/download PDF

141. Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline

Author

Quon, Harry, primary, Vapiwala, Neha, additional, Forastiere, Arlene, additional, Kennedy, Erin B., additional, Adelstein, David J., additional, Boykin, Holly, additional, Califano, Joseph A., additional, Holsinger, F. Chris, additional, Nussenbaum, Brian, additional, Rosenthal, David I., additional, Siu, Lillian L., additional, and Waldron, John N., additional

Published
2017
Full Text
View/download PDF

142. A matched comparison of human papillomavirus–induced squamous cancer of unknown primary with early oropharynx cancer

Author

Ross, Richard Blake, primary, Koyfman, Shlomo A., additional, Reddy, Chandana A., additional, Houston, Narcissa, additional, Geiger, Jessica L., additional, Woody, Neil M., additional, Joshi, Nikhil P., additional, Greskovich, John F., additional, Burkey, Brian B., additional, Scharpf, Joseph, additional, Lamarre, Eric D., additional, Prendes, Brandon, additional, Lorenz, Robert R., additional, Adelstein, David J., additional, and Ward, Matthew C., additional

Published
2017
Full Text
View/download PDF

145. Prognostic factors associated with benefit to post-operative chemotherapy: A National Cancer Data Base analysis.

Author

Geiger, Jessica Lyn, primary, Woody, Neil McIver, additional, Reddy, Chandana A., additional, Koyfman, Shlomo A., additional, Joshi, Nikhil Purushottam, additional, Bodmann, Joanna, additional, Harr, Bridgett Ann, additional, Ives, Denise I., additional, Ferrini, Jodi, additional, Burkey, Brian, additional, Scharpf, Joseph, additional, Lamarre, Eric, additional, Prendes, Brandon, additional, Lorenz, Robert, additional, and Adelstein, David J., additional

Published
2017
Full Text
View/download PDF

147. Do patients learn from survivorship care plans?

Author

Bodmann, Joanna, primary, Harr, Bridgett Ann, additional, Rybicki, Lisa A., additional, Koyfman, Shlomo A., additional, Geiger, Jessica Lyn, additional, Funchain, Pauline, additional, Joshi, Nikhil Purushottam, additional, Woody, Neil McIver, additional, Ives, Denise I., additional, Hamker, Jean F, additional, and Adelstein, David J., additional

Published
2017
Full Text
View/download PDF

148. Outcomes of definitive radiotherapy (dRT) and chemo-radiotherapy (dCRT) for loco-regionally confined (LRC) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ).

Author

Karivedu, Vidhya, primary, McNamara, Michael J., additional, Rybicki, Lisa A., additional, Al taii, Haider, additional, Sohal, Davendra, additional, Rodriguez, Cristina P., additional, Videtic, Gregory M.M., additional, Stephans, Kevin L., additional, Ives, Denise I., additional, Bodmann, Joanna, additional, and Adelstein, David J., additional

Published
2017
Full Text
View/download PDF

149. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

Author

Bauman, Julie E., primary, Cohen, Ezra, additional, Ferris, Robert L., additional, Adelstein, David J., additional, Brizel, David M., additional, Ridge, John A., additional, O'Sullivan, Brian, additional, Burtness, Barbara A., additional, Butterfield, Lisa H., additional, Carson, William E., additional, Disis, Mary L., additional, Fox, Bernard A., additional, Gajewski, Thomas F., additional, Gillison, Maura L., additional, Hodge, James W., additional, Le, Quynh-Thu, additional, Raben, David, additional, Strome, Scott E., additional, Lynn, Jean, additional, and Malik, Shakun, additional

Published
2016
Full Text
View/download PDF

150. Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects

Author

Ward, Matthew C., primary, Ross, Richard Blake, additional, Koyfman, Shlomo A., additional, Lorenz, Robert, additional, Lamarre, Eric D., additional, Scharpf, Joseph, additional, Burkey, Brian B., additional, Joshi, Nikhil P., additional, Woody, Neil M., additional, Prendes, Brandon, additional, Houston, Narcissa, additional, Reddy, Chandana A., additional, Greskovich, John F., additional, and Adelstein, David J., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results